Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study
Open Access
- 4 June 2010
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 257
Abstract
Since 1999, patients presenting with brain metastases (BM) from breast cancer (BC) are treated in our institution with a carmustine (BCNU) - methotrexate (MTX) combination. We report here our clinical experience regarding this combination.Keywords
This publication has 36 references indexed in Scilit:
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Survival in patients with brain metastases from breast cancerCancer, 2008
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinomaCancer, 2006
- Systemic high-dose intravenous methotrexate for central nervous system metastasesJournal of Neuro-Oncology, 2005
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958